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1. Introduction 
The allergic conjunctivitis (AC) consists of five clinical types, a seasonal allergic 
conjunctivitis (SAC), perennial allergic conjunctivitis (PAC), vernal keratoconjunctivitis 
(VKC), atopic keratoconjunctivitis (AKC) and giant papillary conjunctivitis (GPC), having a 
common causal background, namely the involvement of allergic component, but different 
clinical features. 1-5 The five clinical types of AC can occur in 2 basic forms, a primary and a 
secondary form, with respect to the locality of the initial antigen-antibody/sensitized Th1 
cells interaction with following steps, called initial allergic reaction. 6-12 In the primary AC 
forms, the initial allergic reaction with all subsequent steps, due to the direct exposure of 
conjunctivae by an external allergen, is localized in the conjunctival tissue. In these, classical, 
AC forms, the conjunctival tissue is the primary site of allergic reaction and together the 
primary target tissue affected directly by the allergic reaction and displaying the 
characteristic clinical symptoms. In the secondary AC forms, the initial allergic reaction 
taking place in the nasal mucosa, due to exposure to an external allergen, induces 
subsequently the secondary form of AC through various possible mechanisms and 
pathways. In this case, the conjunctival tissue is affected by factors released and generated 
by allergic reaction in the nasal mucosa and the conjunctival response displaying 
characteristic clinical symptoms may be considered as a consequence of the primary allergic 
reaction in the nose. 6-12 
In both the basic forms of AC as well as all five clinical types, various hypersensitivity 
mechanisms, such as immediate type (IgE-mediated Type I), late (Type III) or delayed (cell-
mediated Type IV), may be involved.1, 2, 5, 9-19 The involvement of various hypersensitivity 
types in AC results then in development of various types of conjunctival response (CR) to 
allergen exposure (challenge), an immediate (ICR), a late (LCR), a dual late (DLCR, being a 
combination of an immediate and a late type), a delayed (DYCR) and a dual delayed 
(DDYCR, being a combination of an immediate and a delayed type). 1- 3, 5-14, 20 The primary 
forms of AC can be demonstrated by direct conjunctival provocation tests with allergens 
(CPTs), whereas the secondarily induced AC forms can only be confirmed by nasal 
provocation tests with allergens (NPTs) in combination with registration of the conjunctival 
signs and subjective symptoms. 
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Nevertheless, there is a great dearth of data concerning both the clinical and the 
immunologic features of the secondary CR and the mechanism(s) through which the allergic 
reaction initiated in the nasal mucosa induces the secondary CR types. 1-3, 5-42 The purpose of 
this study was to investigate: (1) the appearance and possible concentration changes of some 
important mediators, such as histamine, tryptase, eosinophil cationic protein (ECP), 
leukotrienes, myeloperoxidase (MPO) and cytokines, such as, interferon-γ (IFN-γ), IL-2, IL-4 
and IL-5 in tears during the secondary late CR; (2) the possible significance of these 
mediators in tears for the mechanism(s) underlying the secondary late CR. 
2. Material and methods 
2.1 Patients 
Thirty-one patients suffering from allergic conjunctivitis (SAC, n=13 and PAC, n=18) for 
more than 3 years, showing insufficient therapeutic compliance to the standard topical 
ophthalmologic treatment, having been referred to our Department of Allergology & 
Immunology (Institute of Medical Sciences “De Klokkenberg”, Breda, The Netherlands), for 
more extensive diagnostic analysis of their AC complaints, and developing the secondary 
late conjunctival response(SLCR) to nasal provocation tests with allergens (NPTs),were 
randomly selected and volunteered to participate in this study. 
These patients, 12 males and 19 females, 18-47 years of age (Table 1), have previously been 
treated with various topical and oral H1-receptor-antagonists, ophthalmic cromolyn 
formulation, topical ocular glucocorticosteroids, decongestant, topical vasoconstrictors and 
incidentally with NSAID drugs, without significant therapeutic effects. None of these 
patients suffered from other ocular disorders, infection, systemic diseases or 
immunodeffociency or had previously been treated with nasal cromolyn, nasal or systemic 
glucocorticosteroids, immunosuppressive drugs or immunotherapy. All of them 
demonstrated normal intraocular pressure. In 14 of these patients 19 conjunctival 
provocation tests (CPT) with inhalant allergen, performed previously, were negative. 
The patients underwent a routine diagnostic procedure consisting of: a detailed disease 
history, general physical examination, basic laboratory tests, bacteriological screening of 
tears, nasal secretions, sputum and blood, roentgenogram of chest and paranasal sinuses in 
Water’s projection, nasoscopy and cytologic examination of nasal secretions, skin tests with 
basic and supplementary inhalant and food allergens, determination of serum 
immunoglobulins, and ophthalmologic examination including ophthalmoscopy, slit-lamp 
evaluation, vital staining with fluorescein and cytologic examination of the tears. The 
routine diagnostic procedure performed in these 31 patients revealed positive or suspect 
history for nasal allergy (93%), positive skin (intracutaneous) tests with various inhalant 
allergens (100%), hyperaemic /livid and edematic nasal mucosa (97%), increased eosinophil 
and neutrophil counts in nasal secretions (87%), conjunctival hyperaemia and tearing to a 
slight degree (100%), appearance of incidental eosinophils and conjunctival epithelial cells in 
the tear specimens (84%), increased blood eosinophil counts (23%), positive specific IgE in 
the serum (ImmunoCAP) for some inhalant allergens (19%) and non-increased nasal 
responsiveness to histamine determined by means of nasal challenge with histamine (93%) 
(Table 1). No other abnormalities were found in these patients. 
In these 31 patients, 54 nasal provocation tests (NPTs) with various inhalant allergens (Table 
2)and 31 control challenges with PBS (phosphate-buffered saline)were performed using 
rhinomanometry in combination with simultaneous recording of the ocular signs and 
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subjective symptoms (Tables 1, 2). The ocular signs and relevant subjective symptoms were 
evaluated by means of the Pelikan’s scoring (grading) system (Table 3). 7, 9-12 The patients 
were investigated in a period without acute ocular and/or nasal complaints, without 
symptoms of an acute infection, outside the allergen-relevant period (season) and during. 
hospitalization. The long-acting H1-receptor antagonists, topical cromolyn and 
glucocorticosteroids were withdrawn 4 weeks, topical and oral short-acting H1 receptor 
antagonists, topical decongestants and other treatments were withdrawn 48 hours before 
each of the NPTs. 
 
 
Patients 
Control subjects 
n=14  SAC 
(n=13) 
PAC 
(n=18) 
Age (years) 25 ± 7 31 ± 12 29 ± 9 
Sex (M/F) 5/8 7/11 6/8 
Disease history (years) 3.9±1.5 4.6±0.7 5.2 ± 1.1 
Blood leukocyte count (x 109 /L) ° 8.3±0.6 9.1±1.4 7.9±0.8 
-increased 0 0 0 
Blood eosinophil count (x 106 /L) °° 263±21 285±13 255±29 
-increased 2 5 4 
Increased total IgE in the serum ▫ 0 0 0 
Positive specific IgE in the serum ▫▫ 1 5 2 
Positive skin response     
-Immediate type 4 7 8 
-Late type 9 10 5 
-Delayed type 0 1 1 
Nasal provocation tests    
-positive 13 18 21 
-negative  10 13 15 
SAC= seasonal allergic conjunctivitis; PAC= perennial allergic conjunctivitis; ° = normal value 4.0-10.0 x 
109/L; °° = normal value < 300 x 106/L; ▫ = normal value <500 IU/mL; ▫▫ = normal value <0.70 U/mL;  
= positive skin response to the relevant allergen (=allergen producing positive nasal and conjunctival or 
nasal response only) 
Table 1. Characteristics of the patients  
The 31 positive NPTs producing the secondary late conjunctival response (SCLR) in these 
patients and 31 PBS control challenges were repeated 2-3 weeks later. The repeated NPTs 
and PBS control challenges were supplemented with a collection of the tears for the 
mediator determination (Table 4). A 4-day interval was always inserted between the end of 
the preceding test and the begin of the following test to prevent the carry-over effects and to 
allow the patient recovery. The study protocol was approved by the local ethical committee 
and informed consent was obtained from all study participants. 
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Allergen Concentration 
Nasal 
responses 
positive 
(n=31) 
Conjunctival 
responses (n=31) 
Nasal 
responses 
negative 
(n=23) 
SAC 
(n=13) 
PAC 
(n=18) 
Dermatophagoides pteron 1000 BU/mL 5  5 3 
Dermatophagoides farinae  1000 BU/mL 1  1 1 
Animal danders      
 -dog 3000 BU/mL 3  3 2 
 -horse 2000 BU/mL 2  2 0 
 -cat 2000 BU/mL 2  2 3 
 -guinea pig  2000 BU/mL 1  1 0 
Feathers      
 -parrot  3000 BU/mL 1  1 0 
 -parakeet 3000 BU/mL 1  1 1 
Aspergillus fumigatus  1000 BU/mL 2  2 1 
Pollen      
 -grass mix I 1000 BU/mL 4 4  2 
 -grass mix II 1000 BU/mL 2 2  1 
 -flower mix 5000 BU/mL 1 1  2 
 -tree mix 3000 BU/mL 2 2  3 
 -weed mix 1000 BU/mL 1 1  2 
 -poplar  2000 BU/mL 1 1  0 
 -ragweed short 1000 BU/mL 1 1  1 
 -ragweed giant  1000 BU/mL 1 1  1 
SAC = seasonal allergic conjunctivitis; PAC = perennial allergic conjunctivitis; BU/mL = biologic units 
per mL 
Grasspollen mix I = Dactylis glomerata, Lolium perenne, Phleum pratensis, Poa pratensis; 
Grasspollen mix II = Festuca pratensis, Holcus lanatus, Agrostis alba, Anthoxanthum odoratum 
Flower pollen mix = Dahlia variabilis, Solidago virgaurea, Primula variabilis, Forsythia suspensa 
Tree pollen mix = Betula pendula, Corylus avellana, Juniperus communis, Salix alba 
Weed pollen mix = Artemisia vulgaris,Plantago lanceolata, Rumex acetosa, Taraxacum officinale 
Table 2. Survey of the allergens used for nasal challenge 
2.2 Allergens 
Dialyzed and lyophilized allergen extracts (Allergopharma, Reinbek, Germany) were 
diluted in phosphate-buffered saline (PBS) and used for skin tests in concentrations of 100-
500 BU/mL and for NPTs in concentrations of 1000-5000 BU/mL (Table 2), as recommended 
by the manufacturer. If indicated, higher dilutions of the allergen extracts were used both 
for the skin tests and for the NPTs. 
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2.3 Skin tests 
Scratch tests with allergenic extracts in concentrations of 500 BU/mL were performed and 
the results evaluated after 20 minutes. If the results were negative, then intracutaneous tests 
in concentrations of 100 BU/mL and 500 BU/mL were carried out and evaluated 20 minutes 
and 6, 12, 24, 36, 48, 56, 72 and 96 hours after the intradermal injection. A skin wheal (>7.0 
mm in diameter) occurring after 20 minutes was qualified as a positive immediate skin 
response, the skin infiltration appearing between 6 and 12 hours as a late skin response, and 
the skin induration recorded later than 48 hours as a delayed skin response.8-13, 42-46 
2.4 Nasal provocation tests (NPTs) 
Nasal challenges with allergens were performed using rhinomanometry, already 
described in our previous studies. 6-13, 23, 43-47 The nasal obstruction due to the edema of the 
nasal mucosa was evaluated by means of nasopharynx-nostril pressure gradient (NPG) 
parameters, which are the pressure differences (∆P) between the nasopharyngeal cavity 
and the outside air, expressed in cm H2O. NPTs were performed using the following 
schedule: (1) baseline values recorded at 0, 5 and 10 minutes before the challenge; (2) PBS 
control values recorded at 0, 5 and 10 minutes after a 3-minute application of PBS to the 
nasal mucosa of the non-intubated nasal cavity by means of a saturated wad of cotton 
wool on a nasal probe inserted under the middle turbinate; (3) post-challenge values 
recorded after a 3-minute challenge with allergen, carried out in the same manner as the 
challenge with PBS, at 0, 5, 10, 20, 30, 45, 60, 90 and 120 minutes, then every hour up to the 
12th hour, and every second hour during the time-periods between the 24th-38th and 48th – 
56th (60th) hour.9-13 The allergens used for the NPTs were chosen with respect of the 
disease history and positive skin tests (Tables 1, 2). The nasal response (NR) was assessed 
to be positive when the post-challenge mean NPG values increased by at least 2.0 cm H2O 
(1.2 ± 0.3, mean± SE) with respect to the mean baseline values, recorded at least at three 
consecutive time intervals14, 23-26. The NPG changes recorded within 60-120 minutes after 
the allergen challenge were considered to be an immediate NR (INR), those recorded 
within 4-12 hours to be a late NR (LNR), and the changes measured later than 24 hours to 
be a delayed NR (DYNR) 9-13,.43-45 
2.5 Control tests with phosphate-buffered saline (PBS) 
The control nasal challenge with PBS was performed in each patient studied by the same 
schedule as that used for the NPTs with allergen, however 3 days later. 
2.6 Conjunctival response 
The objective conjunctival signs and relevant subjective symptoms were registered before 
and during all NPTs with allergens and PBS at the same time-points as the nasal NPG 
values. The features of the conjunctiva were assessed by ophthalmoscopy including a slit 
lamp. The conjunctival signs, hyperaemia (injection), chemosis, hyperlacrimation, and 
palpebral edema, and the subjective symptoms, such as itching (burning), blurred vision 
and photophobia, were registered and evaluated by means of the scale suggested by 
Abelson, however, modified by us (Pelikan’s scale). 10-12 The evaluation criteria of the 
individual signs and symptoms were as follows: 0=absent, 1=mild (present to a slight 
degree), 2=moderate, 3= pronounced (moderately severe), 4=severe (Table 3 ). The 
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differences in total sign score of 4 points or more ( 3 ± 1, mean ± SE), recorded at least at 
three consecutive time-intervals, were found to be statistically significant (p<0.05). 
 
 
Abelson I* Abelson II** Pelikan 
I. OBJECTIVE SIGNS    
-Hyperemia (injection, redness) 0 - 4 0 - 3 0 - 4 
-Chemosis  0 - 3 0 - 4 
-Hyperlacrimation (tearing)  0 - 3 0 - 4 
-Palpebral edema    0 - 4 
    
II. SUBJECTIVE SYMPTOMS    
-Itching (burning) 0 - 4 0 - 4 0 - 4 
-Photophobia    0 - 4 
-Blurred vision   0 - 4 
* = References 27, 28, 29; ** = References 21, 30 
Abelson’s grading scale: 0=None; 1=Mild (intermittent); 2=Moderate; 3=Severe;  
 4= extremely severe (or “incapacitating “itching); [Significant threshold: ≥+2] 
Pelikan’s grading scale: 0=Absent; 1=Mild (present to a slight degree or intermittent); 
 2=Moderate; 3= Pronounced (moderately severe); 4=Severe; [Significant difference: 
≥4 points (p<0.05), with respect to the pre-challenge value, recorded at least at 3 consecutive 
time-points]. 
Table 3. Survey of Abelson’s and our “modified” conjunctivitis grading scale and symptom 
score (“Pelikan’s modified grading scale”) 
2.7 Collection and processing of tears 
The tear specimens were collected from each of eyes separately by means of a 
micropipette from the inferior conjunctival fornix and/or lacus lacrimalis, before, 30 and 
60 minutes, every second hour up to 12 hours and 24 hours after the allergen challenge. If 
necessary, a gentle pressure on the lacrimal sac from outside was applied. The tear 
samples (1-4 mL ) were stored at -8ºC and processed within 1 hours. The concentrations of 
appropriate factors in tears were measured by using commercially available kits, 
following the manufacturer’s recommendations. The measurements of the factors were 
performed separately in tear samples from each of the eyes on each occasion, and the 
results were then calculated as the mean of both the eyes. 
All measurements were performed in duplicate by a double-blind schedule. The intra-
assay as well as the inter-assay coefficients of variations for all the assay kits employed 
were less than 10 %. 
a. Histamine Histamine concentrations, so-called “blanks”, were measured by the 
Siraganian’s fluorometric method 48 Detection limits (DL): 1.0 ng/mL 
b. Tryptase -ImmunoCAP (Pharmacia, Uppsala, Sweden). DL: 1.0 μg/L 
c. Eosinophil cationic protein (ECP)-ImmunoCAP (Pharmacia Diagnostics, Uppsala, 
Sweden). DL: 2μg/L 
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d. Leukotrienes B4, C4, E4 -EIA kits (Cayman Chemical Company, Ann Arbor/MI, USA). 
Detection limits (DL): LTB4 = 4.8 pg/mL; LTC4 = 2 pg/mL; LTE4 = 3.7 pg/ 
e. Myeloperoxidase (MPO) - ELISA kit (Oxis International Inc, Portland /OR, USA). DL: 25 
ng/mL  
f. Interferon-gamma (IFN-γ) - ELISA kit (Bender MedSystems, Wien, Austria). DL: 1.0 
pg/mL  
g. Interleukin 2 (IL-2) - ELISA kit (R & D System (Minneapolis/MN, USA). DL: < 3.0 
pg/mL  
h. Interleukin 4 (IL-4) - ELISA kit (Bender MedSystems , Wien, Austria).DL: 0.6 pg/mL 
i. Interleukin 5 (IL-5) - ELISA kit (R & D System (Minneapolis/MN, USA). DL: 3.0 
pg/mL 
2.8 Control group 
Fourteen adults suffering from allergic rhinitis, confirmed by positive history, skin tests and 
positive NPTs with inhalant allergens, but without history of any ocular disease and with 
normal ophthalmologic findings, volunteered to participate as control subjects. In these 
patients 14 positive late nasal responses (LNR)with inhalant allergens were repeated and 
supplemented with registration of the conjunctival features and subjective symptoms and 
estimation of the above mentioned mediators in tears. 
2.9 Statistical analysis 
1. Nasal and conjunctival responses (mean total scores of conjunctival signs and subjective 
symptoms) to the allergen challenge as well as to the PBS control challenge in 
individual patients were statistically analyzed by Wilcoxon matched-pair signed rank 
test, comparing the post-challenge values at each of the time-points with the mean pre-
challenge (baseline) values. 
2. The mean NPG values and the mean total conjunctival score values were compared 
with corresponding PBS control values at each of the time-points and analyzed by the 
Mann-Whitney U test. 
3. The post-challenge mediator values measured at each of the time points during the 
repeated SLCRs and PBS control in individual patients were compared with their pre-
challenge values and statistically analyzed by Wilcoxon matched-pair signed rank 
test. 
4. The mean post-challenge mediator values during the repeated SLCRs were compared 
with corresponding PBS values and statistically evaluated by Mann-Whitney U test. 
Statistical evaluation of the CR was performed separately for each of the eyes and then 
the mean from both the eyes was calculated. A P value < 0.05 was considered to be 
statistically significant. 
3. Results 
3.1 Nasal responses (NRs) 
In the 31 patients 54 nasal provocation tests (NPTs) with various inhalant allergens (Tables 
1, 2) and 31 PBS control challenges were performed. The 31 patients developed 31 late nasal 
responses (LNRs; p<0.01) and 23 negative nasal responses (NNRs; p>0.1)(Table 2). The LNR 
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began between 4-6 hours, reached its maximum between 6-8 hours and resolved within 12 
hours after the nasal challenge with allergen. 
The 31 PBS control tests were all negative (p>0.1). No significant differences were found in 
the appearance of the LNRs with respect to the individual allergens (p>0.1). The LNRs were 
associated with significant changes (p<0.05) in the counts (mostly temporary increase) of the 
neutrophils, eosinophils, epithelial and goblet cells, and to a lesser degree of the 
lymphocytes, in the nasal secretions. The counts of basophils, mast cells, monocytes and 
plasma cells were relatively low and without significant changes. 
The repeated NPTs resulted in the development of similar and statistically significant LNRs 
as comparing the post-challenge with the pre-challenge (baseline) values (p<0.001) and with 
the PBS control values (p<0.001) (Fig. 1C ). No statistical significant differences were found 
between the initial and the repeated LNRs (p>0.2). 
3.2 Conjunctival responses (CRs) 
The 31 positive LNRs, recorded in 31 patients, were associated with significantly positive 
secondary conjunctival responses of the late type (SLCR; p<0.01)(Table 2). The positive 
SLCR began between 5-6 hours, reached its maximum between 8-10 hours and resolved 
usually within 12, sometimes within 24 hours after the allergen challenge. The SLCR was 
represented by significant changes of the objective conjunctival signs (p<0.01) as well as 
subjective symptoms (p<0.05). No significant corneal signs were recorded in any SLCR. 
No conjunctival changes were recorded during the 23 negative nasal responses (p>0.05) or 
during the 31 PBS control challenges (p>0.1). The 31 repeated NPTs , have induced similar 
and statistically significant SLCRs , both as comparing the post-challenge with the pre-
challenge (baseline) values (p<0.01) and as comparing with the PBS control challenge 
(p<0.01). (Fig. 1B). No statictically significant difference were found between the initial 
and the repeated SLCRs (p>0.2). No significant differences in the conjunctival changes 
recorded both during the initial and during the repeated SLCRs were observed between 
the right and left eye (p>0.1). 
3.3 Changes of mediators and other factor in the tears during the SLCRs 
The SLCRS were associated with significant changes in the concentrations (p<0.05) of 
histamine, EPC, LTC4 , LTB4 , MPO, IL-4 and IL-5 in the tears (Table 4; Fig. 1A). The pre-
challenge concentrations of most of these factors were either very low or under the detection 
limit, whereas their post-challenge concentrations usually increased to various degrees at 
various time-points, followed by their decrease and disappearance from the tears within 24 
hours after the allergen challenge (Table 4 ; Fig.1A). The concentrations of tryptase in tears 
was very low, sometimes under the detection limit and without significant changes (p>0.05). 
The INF-γ and IL-2 were recorded in the tears during the SLCRs irregularly and without 
any significant changes (p>0.05 and p>0.05, respectively). The LTE4 was not detected in the 
tears during the positive SLCRs. No significant concentration changes of the investigated 
factors were recorded in tears during the 31 PBS control challenges and 23 negative CRs. 
Moreover, the concentrations of most of these factors were under the detection limits (Table 
4). No significant differences in the concentrations of particular factors and their changes in 
tears have been found between the right and left eye, both during the SLCRs and during the 
PBS controls (p>0.1 and p>0.2, respectively). 
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Fig. 1. The secondary late conjunctival responses (SLCRs; n=31) accompanying the isolated late 
nasal responses (ILNRs; n=31). A. The mean score of particular factors during the SLCR: □ = 
histamine, Δ = tryptase, ⌖ = EPC, ⍋ = LTB4 , ⃟ = LTC4 , ✶ = MPO, ■ = IL-4, ▲ = IL-5, ♦ = IFN-
γ,  = IL-2. B. The total mean score of conjunctival signs and symptoms during the SLCR (●) 
and PBS (x). C. The mean rhinomanometric values (NPG) recorded during ILNR (○) and PBS 
(x), I = Initial (baseline) values; PBS = Phosphate buffered saline; ALL = Allergen challenge 
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Before 
the 
challenge 
After the challenge (hours) 
½ 1 2 3 4 5 6 7 8 9 10 11 12 24 28 
Histamine 
ng/mL 
                
- SLCR < 1.0 < 1.0 < 1.0 < 1.0
2.6 ± 
0.3* 
4.7 ± 
0.5* 
3.4 ± 
0.7* 
1.9 ± 
0.6+ 
1.2 ± 
0.1 
<1.0 <1.0 <1.0 <1.0 <1.0 <1.0 
1.3 ± 
0.2 
- PBS < 1.0 < 1.0 < 1.0 < 1.0 <1.0 <1.0 
1.1 ± 
0.1 
<1.0 <1.0 <1.0 <1.0 <1.0 <1.0 <1.0 <1.0 <1.0 
Tryptase 
μg/L                 
- SLCR 1.3±0.3 <1.0 <1.0 
1.1 ± 
0.1 
<1.0 
1.3 ± 
0.2 
<1.0 <1.0 <1.0 <1.0 <1.0 <1.0 <1.0 <1.0 <1.0 <1.0 
- PBS < 1.0 <1.0 <1.0 <1.0 
1.2 ± 
0.2 
<1.0 <1.0 <1.0 <1.0 <1.0 <1.0 <1.0 <1.0 <1.0 <1.0 <1.0 
EPC 
μg/L                  
- SLCR 2.3±0.2 
2.5 ± 
0.4 
2.2 ± 
0.1 
4.5 ± 
0.7+ 
5.3 ± 
1.1+ 
9.5 ± 
2.3* 
13.8 ± 
3.2**
15.6 ± 
2.0**
7.3 ± 
1.8* 
6.0 ± 
1.4* 
2.4 ± 
0.2 
<2.0 <2.0 <2.0 <2.0 <2.0 
- PBS 2.7±0.6 <2.0 <2.0 
2.4 ± 
0.4 
2.5 ± 
0.3 
<2.0 <2.0 
2.8 ± 
0.5 
2.3 ± 
0.3 
2.5 ± 
0.2 
2.1 ± 
0.1 
2.2 ± 
0.1 
<2. 
2.4 ± 
0.3 
<2. <2. 
LTB4 
pg/mL 
                
- SLCR <4.8 <4.8 <4.8 
5.5 ± 
0.6 
4.9 ± 
0.1 
6.8 ± 
1.0+ 
9.3 ± 
2.1* 
11.2 ± 
3.1* 
23.0 ± 
2.6**
28.5 ± 
1.4**
10.7 ± 
1.9* 
6.6 ± 
0.5+ 
5.1 ± 
0.4 
5.0 ± 
0.2 
<4.8 <4.8 
- PBS <4.8 <4.8 <4.8 
5.1 ± 
0.2 
<4.8 <4.8 <4.8 <4.8 5.0±0.2 <4.8 <4.8 <4.8 <4.8 <4.8 <4.8 <4.8 
LTC4 
pg/mL 
                
- SLCR 2.2±0.1 <2.0 <2.0 
2.3 ± 
0.3 
3.8 ± 
0.7+ 
5.2 ± 
0.5* 
6.1 ± 
0.4* 
5.8 ± 
0.3* 
4.9 ± 
0.8* 
3.3 ± 
0.2 
2.3 ± 
0.2 
<2.0 <2.0 <2.0 <2.0 <2.0 
- PBS <2.0 <2.0 <2.0 <2.0 <2.0 <2.0 <2.0 <2.0 <2.0 
2.2 ± 
0.2 
2.1 ± 
0.1 
<2.0 <2.0 <2.0 <2.0 <2.0 
MPO 
ng/mL 
                
- SLCR <25.0 <25.0 <25.0 <25.0 <25.0 <25.0
31.9 ± 
5.5+ 
43.8 ± 
3.6* 
51.5 ± 
4.0**
45.1 ± 
2.8* 
34.2 ± 
1.7* 
26.3 ± 
1.0 
<25.0 <25.0 <25.0 <25.0 
- PBS <25.0 <25.0 <25.0 <25.0 <25.0 <25.0
28.6 ± 
2.7 
<25.0 <25.0 <25.0 <25.0 <25.0 <25.0 <25.0 <25.0 <25.0 
IFN-γ 
pg/mL 
                
- SLCR <1.0 <1.0 <1.0 <1.0 <1.0 <1.0 <1.0 <1.0 <1.0 <1.0 <1.0 <1.0 
1.2 ± 
0.1 
1.2 ± 
0.2 
<1.0 <1.0 
- PBS <1.0 <1.0 <1.0 <1.0 <1.0 <1.0 <1.0 <1.0 <1.0 <1.0 <1.0 <1.0 <1.0 <1.0 <1.0 <1.0 
IL-2 
pg/mL 
                
- SLCR < 3.0 < 3.0
3.2 ± 
0.2 
<3.0 <3.0 <3.0 <3.0 <3.0 <3.0 
3.3 ± 
0.3 
<3.0 <3.0 <3.0 
3.2 ± 
0.1 
<3.0 <3.0 
- PBS < 3.0 < 3.0 < 3.0 < 3.0 < 3.0
3.1 ± 
0.1 
< 3.0 < 3.0 < 3.0 < 3.0 < 3.0 < 3.0 < 3.0 < 3.0 < 3.0 < 3.0 
IL-4 
pg/mL 
                
- SLCR <0.6 <0.6 <0.6 <0.6 
2.4 ± 
1.0+ 
5.7 ± 
0.8* 
7.9 ± 
1.5**
4.0 ± 
0.6* 
1.8 ± 
0.5 
<0.6 <0.6 <0.6 <0.6 <0.6 <0.6 <0.6 
- PBS <0.6 <0.6 <0.6 <0.6 <0.6 <0.6 <0.6 <0.6 <0.6 <0.6 <0.6 <0.6 
1.3 ± 
0.4 
<0.6 <0.6 <0.6 
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Before 
the 
challenge 
After the challenge (hours) 
½ 1 2 3 4 5 6 7 8 9 10 11 12 24 28 
IL-5 
pg/mL 
                
- SLCR <3.0 <3.0 <3.0 <3.0 <3.0 <3.0 <3.0 <3.0 <3.0 
3.7 ± 
0.6 
4.6 ± 
0.4* 
4.3 ± 
0.7* 
3.8 ± 
0.2 
<3.0 <3.0 <3.0 
- PBS <3.0 <3.0 <3.0 <3.0 <3.0 <3.0 <3.0 <3.0 <3.0 <3.0 <3.0 <3.0 <3.0 <3.0 
3.1 ± 
0.1 
<3.0 
SLCR = Secondary late conjunctival response; PBS = Phosphate-buffered saline; Significance of mean 
post-challenge values with respect to the mean pre-challenge (baseline) value:  
+ = p≤0.05; * = p<0.05; ** = p<0.01 
Table 4. Concentration of particular factors in tears during the secondary late conjunctival 
response (SLCR) 
3.4 Control patients 
The 14 control patients developed an isolated late nasal response (ILNR) during the initial as 
well as the repeated NPTs (p<0.001 and p<0.001 respectively). No significant conjunctival 
signs or subjective symptoms were recorded during the 14 repeated LNRs (p>0.2). No 
significant changes in concentrations of the investigated factors were recorded in tears 
during the repeated LNRs in these control patients. 
4. Discussion 
The relationship between the conjunctivae and the nose includes both the anatomical and 
the functional aspect. 1, 10-12 The conjunctiva is connected with the nasal cavity not only by 
means of the naso-lacrimal duct, being a part of lacrimal ways, through which opening 
the tear drainage into the nasal cavity is facilitated, but also by means of the blood vessel 
network, lymphatic tissue system and neurogenic network. All of them express a number 
of mutual links and share various common properties.1, 10-12 Allergic reactions taking place 
primarily in the nasal mucosa due to the intranasal exposure to inhalant allergen may 
affect the conjunctiva and subsequently also other ocular tissues, such as the cornea, in 
various ways and upon involvement of various mechanisms.9-12, 33, 49-58 These mechanisms 
may include: (1) Various cell types participating in the allergic reaction occurring in the 
nasal mucosa, such as mucosal mast cells, eosinophils, basophils, neutrophils, B-
lymphocytes/plasma cells, particular subsets of T-lymphocytes (Th`1, Th2, Th 17, T-
regulatory cells, natural killer cells), dendritic cells, monocytes thrombocytes, 
macrophages, epithelial and endothelial cells, and mucosal goblet cells, can migrate into 
the bloodstream and/or lymphatic system, and under extreme conditions also into 
lacrimal ways, and thereby attain the conjunctiva; (2) The various cell types, activated 
and/or inhibited during the allergic reaction in the nasal mucosa, generate and release a 
number of factors (classical mediators, eicosanoids, cytokines, chemokines, adhesion 
molecules, chemotactic and other factors), which could then reach conjunctiva either 
directly by the retrograde penetration through the naso- lacrimal duct and lacrimal ways 
or indirectly through the related blood and/or lymphatic vessel system; (3) The allergic 
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reaction could also activate the local neurogenic system (sensory nerves, sympathetic and 
parasympathetic fibres) releasing then the neuropeptides which can reach the conjunctiva 
either along or through the related nerves, such as nervus trigemini, nervus nasociliaris 
and ganglion pterygopalatinum; (4) The allergic reaction or its particular stages and parts 
can also stimulate the local nasal mucosal lymphatic system called “nose-associated 
lymphatic tissue” (NALT), being a part of the“mucosa- associated lymphatic system” 
(MALT). The MALT system facilitates a multiple and mutual communication among the 
particular lymphatic organ-related sub-systems, in this case between the NALT on one 
hand and the “eye-associated lymphatic tissue “(EALT), “conjunctiva- associated 
lymphatic tissue”(CALT), “tear-associated lymphatic tissue “(TALT) and “lacrimal 
drainage-associated lymphatic tissue”(LDALT) on the other hand. The abundance of the 
relationship and communication among the individual parts of lymphatic system allow 
not only a multiple transmission of various signals (e.g. cell-cell, cell-receptor, receptor-
receptor), but also a reciprocal (both- directional) traffic of various types of circulating 
cells, such as B-lymphocytes/plasma cells producing immunoglobulins of individual 
classes and sub-classes, particular sub-sets of T-lymphocytes (Th1- and Th2-cells, 
cytotoxic, regulatory and natural killer cells), antigen-presenting cells (APC), other cell 
types, or finally, under certain circumstances, of some cells resident in the mucosal 
membrane. 
The cell traffic can be effectuated not only through various attraction mechanisms governed 
by chemotactic factors, cytokines, chemokines and adhesion molecules, but also through a 
special, so-called, “homing mechanism” of B- and T-lymphocytes, controlled by a number of 
homing factors.10-12, 55, 56 
The disturbed homing mechanism leads to migration of particular cell types (e.g. B- or T-
lymphocytes) to locations different from the predetermined destinations. By this way, the 
particular sub-sets of lymphocytes having been initially activated in a certain tissue 
(mucosal locality), after migrating into the bloodstream and/or lymphatic network to finish 
their maturation process, do not return to this original tissue, but due to the disturbed 
homing factors they terminate their route by entering into another tissue, different from the 
original one. This process is called “wrong homing”. 10-12, 45-56 
The occurrence and possible role of various mediators, cytokines, chemokines and adhesion 
molecules in tears has already been extensively studied in patients suffering from various 
forms of allergic conjunctivitis. 14-16, 18, 20, 26, 32-35, 37-42, 57-83  
The mediators having been most frequently studied in tears included histamine,20, 37, 40, 41,59-62, 64, 
66 tryptase,14, 26, 35, 37, 62, 66, 67 ECP,14, 26, 32, 63, 66, 68, 69 LTB4 ,20, 64, 70-74 LTC4 ,20, 37, 41, 73, 74 LTD4,73 MPO, 63, 66 
Prostaglandins (PGD2 , PGE2 ) 41, 60, 62, 72 and various cytokines 1, 3, 5, 12, 16-18, 26, 36, 62, 63, 66, 76-83 
In most of these studies a single determination of the mediators in tears of patients suffering 
from primary forms of allergic conjunctivitis (SAC, PAC) or keratoconjunctivitis (VKC, 
AKC) has been performed. The papers addressing the determination of the mediators 
during the conjunctival provocation tests with allergens (CPTs) are not numerous.14, 20, 26, 32, 
35, 37, 38, 40, 60, 66, 83 Studies following the concentration changes of the above mentioned 
mediators in tears for a longer period of time as a serial determination during the particular 
types of conjunctival response (immediate/ early and/or late) due to the conjunctival 
challenge with allergen are relatively rare.14, 20, 32, 37, 61-63, 83 The primary immediate/early 
conjunctival response (ICR) to conjunctival challenge with allergen (CPT) has been reported 
to be accompanied by concentration changes (mostly increase) of histamine, 14, 20, 26, 37, 38, 40, 41, 
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60-62, 66, 83 tryptase, 14, 35, 37, 62 ECP,63 LTB4 ,20, 73 LTC4 ,20, 37, 41, 73 MPO, 63 PGD2, 41, 60, 83 kinin, 41, 60 
TAME-esterase 41, 60 and various cytokines 62, 63 in tears. The primary late conjunctival response 
(LCR) to conjunctival challenge with allergen (CPT) has been reported to be associated with 
increased concentrations of histamine, 14, 20, 61, 83 ECP,14, 32, 63 LTB4 ,20 LTC4 20and some cytokines 
16, 62 in tears. Our results demonstrating increased concentrations of histamine, EPC, LTB4 , 
LTC4 , MPO in tears during the secondary late conjunctival response (SLCR) would indicate 
their active role in the development of this type of CR. However, they were most probably 
released by the eosinophils, neutrophils and mast cells or basophils in the nasal mucosa, the 
place of the primary allergic reaction due to the initial allergen exposure. This fact may be 
supported by results of our other studies,7, 9, 84 demonstrating only limited numbers of these 
cell types in tears during the later stages of SLCR. Moreover, these cells were in a non-
activated condition, which means their cytoplasmic granules were not degranulated. In 
contrast, the primary LCR due to the direct conjunctival challenge with allergen is usually 
accompanied by the abundant appearance of eosinophils and neutrophils and sporadical mast 
cells, all of them having been exhausted and demonstrating empty cytoplasmic granules 
(=degranulation) (our not yet published data). 
Another interesting result was evidence of slightly increased concentrations of cytokines IL-
4 and IL-5 in the tears, whereas IFN-γ and IL-2 appeared in the tears only irregularly and 
without any concentration changes. This finding may suggest an involvement of Th2 –
lymphocytes in the mechanism leading to the SLCR, however, during the initial phase of 
this mechanism taking place in the nasal mucosa. 
An interesting, but also somewhat conflicting, result was the absence of specific allergen- 
IgE antibody in serum of most the patients developing the SLCR. Moreover, in another 
supplementary pilot study, which results are not shown, we did not record any allergen-
specific IgE antibody in the nasal secretions or even in the tears during the SLCR. This 
finding is then partly in contrast to the increased histamine concentrations in the tears 
during this CR type. The absence of specific IgE antibody in the serum as well as in the 
nasal secretions and tears of the patients developing the SLCR would suggest either that 
the concentration of IgE both in the serum and in the nasal secretions and tears were 
under the detection limits, or a possible involvement of topical IgE being limited to the 
nasal mucosa only and without any migration outside the nasal mucosa, or finally 
involvement of non-IgE mechanism in the SLCR. Unfortunately, at this moment we have 
no acceptable explanation for these phenomena. Further investigation, such as biopsy and 
immunohistochemical methods of the conjunctival and adjacent tissues will be necessary 
to provide more clarity on this field. 
The results of this study would also stress the importance of provocation tests with 
allergens. The conjunctival provocation tests with allergens (CPTs), performed directly on 
the conjunctiva, confirm the role of allergic reaction taking place in the conjunctiva due to a 
direct exposure of conjucntival tissue to an inhalant allergen. The CPTs result in the 
manifestation of various types of primary conjunctival response, such as immediate, late or 
delayed, characterized by various conjunctival signs and subjective symptoms. The CPTs 
are therefore suitable for demonstrating and confirming the primary types of CR. 
Nevertheless, the secondary or secondarily induced CR types can only be demonstrated and 
confirmed by means of nasal provocation tests with allergens (NPTs) combined with 
simultaneous registration of the conjunctival signs and subjective symptoms. An important 
requirement for both the CPTs and NPTs is registration of the particular representative 
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parameters before and repeatedly after the allergen challenge, thus for a sufficiently long 
period of time, allowing measurement of the particular response type in its whole and 
dynamic course. 
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